Intech Biopharm Corporation (TPEX:6461)
15.90
-0.10 (-0.63%)
Aug 19, 2026, 1:30 PM CST
Intech Biopharm Revenue
Intech Biopharm had revenue of 18.83M TWD in the quarter ending June 30, 2026, a decrease of -78.54%. This brings the company's revenue in the last twelve months to 48.55M, down -57.87% year-over-year. In the year 2025, Intech Biopharm had annual revenue of 107.53M with 170.31% growth.
Revenue (ttm)
48.55M
Revenue Growth
-57.87%
P/S Ratio
58.78
Revenue / Employee
n/a
Employees
96
Market Cap
2.85B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 107.53M | 67.75M | 170.31% |
| Dec 31, 2024 | 39.78M | 13.93M | 53.90% |
| Dec 31, 2023 | 25.85M | 2.20M | 9.30% |
| Dec 31, 2022 | 23.65M | -15.25M | -39.21% |
| Dec 31, 2021 | 38.90M | 17.79M | 84.30% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Apex Biotechnology | 1.87B |
| SYN-TECH Chem. & Pharm. | 1.27B |
| Chunghwa Chemical Synthesis & Biotech | 934.29M |
| Sagittarius Life Science | 392.26M |
| BioGend Therapeutics | 236.58M |
| 3D Global Biotech | 159.19M |
| Shine-On BioMedical | 50.62M |
| GlycoNex Incorporation | 36.35M |